摘要:
A method of treatment to avoid bioavailability food effects and improve bioavailability variability, by administering a pharmaceutical dosage form containing a pharmaceutical active agent and a disintegrant in a core, a swellable coating surrounding the core, and an optional enteric coating surrounding the swellable coating.
摘要:
Pharmaceutical compositions comprising memantine or a salt thereof, from which less than about 80% of the contained memantine dissolves into a pH 1.2 aqueous medium within about 60 minutes.
摘要:
This invention relates to a process of mixing of crystalline cefuroxime axetil with amorphous cefuroxime axetil for the preparation of a bioavailable oral dosage form comprising of amorphous cefuroxime axetil containing from 7 to 25% crystalline cefuroxime axetil.
摘要:
A solid pharmaceutical dosage form comprises a substrate containing an active agent and a solid composition deposited onto areas of a surface of the substrate and containing an active agent.
摘要:
The present invention relates to pharmaceutical compositions comprising simvastatin or pharmaceutically acceptable salts, solvates, enantiomers or mixtures thereof, processes for preparing the same and methods of use and treatment.
摘要:
The present invention discloses stable, solid oral pharmaceutical composition comprising Lanthanum carbonate having more than 6 molecules of water per molecule of lanthanum carbonate and pharmaceutically acceptable carriers or diluents, wherein said carrier or diluent excludes monosaccharide/s or disaccharide/s, such that the composition has comparable in-vitro dissolution profile similar to that of FOSRENOL®.Also disclosed is a wet granulation process for making the same.
摘要:
Compositions and/or formulations comprising solifenacin or a salt thereof and processes for preparing the same. Certain compositions and formulations contain a stable amorphous form of solifenacin succinate.
摘要:
Pharmaceutical compositions comprising mesalamine, wherein the compositions are free of a liphophilic matrix, and processes for preparing pharmaceutical compositions comprising mesalamine and being free of a liphophilic matrix.